Marco Valgimigli
@vlgmrc
Followers
2K
Following
442
Media
27
Statuses
567
Passionate physician and researcher, clinical trialist and father of two boys and one daughter and in love with my partner
Lugano, Switzerland
Joined October 2013
Shape the future of #InterventionalCardiology 🚀 Submit your abstract (Oct 16) or clinical case (Oct 23) to #EAPCISummit Munich next 19-20 February. Outstanding works will be published in Eur Heart J Supplements. Join the science that inspires ▶️ https://t.co/iTCN2wIYyx
0
5
11
External Validation of the Mayo Clinic PCI Risk Model. Use single pre-procedural model to calculate 4 outcomes: Mortality, AKI, Bleeding 🩸, and Stroke Thanks 🙏🏽 @vlgmrc @svrao @drdangiolillo @DFCapodanno Our research just got published in JAHA https://t.co/8YP3G1206K
1
10
56
Implications of platelet counts and their dynamics in patients hospitalized with acute coronary syndromes, using MATRIX trial data. Read this article published in @RevEspCardiol by @AndreaZito66 @vlgmrc
https://t.co/gJFwAZ93LF
0
2
3
Christopher Cannon: Clopidogrel Monotherapy is Superior to Aspirin Monotherapy for MACCE Prevention @BrighamWomens | @harvardmed | @TheLancet
@vlgmrc | @DanieleGiacoppo
https://t.co/yESZQDdGrn
#Aspirin #BrighamAndWomensHospital #CAPRIETrial #Clopidogrel #HarvardHeartLetter
0
3
9
#EAPCISummit26 February 19-20 in Munich 🇩🇪 ⏰ SUBMiT YOUR ABSTRACTS by October 16th at 1200 CEST &. CLINICAL CASES by October 23rd at 1200 CEST To #EAPCISummit26 ⏰ https://t.co/Y7Yg4njbj0
@escardio #EAPCI #EAPCISummit26 #science #research #guidelinesinpractise
4
28
46
Seeking for the Boundaries of De-escalation in Antiplatelet Therapy for ACS: New PharmaPulse in #EHJPharmacotherapy 💊 👉 https://t.co/iHStWrMiDG
@EditorEHJCVP 👨💼 @vlgmrc @MattiaGalli10
@escardio @ESC_Journals 📚
academic.oup.com
De-escalation strategies of antiplatelet therapy have been shown to improve outcomes in patients with acute coronary syndrome (ACS).1 However, not all de-e
0
5
11
At 13-month #YesCCT evaluation post-LAA closure, the majority of 45-day LAA patency persists, whereas new onset LAA patency is rare. https://t.co/1BjXcsrMK5
#cvLAAoccluder #JACCIMG #cvImaging @vlgmrc
1
12
42
Dirk Sibbing Shares a Recent ”Excellent Study” on Clopidogrel Versus Aspirin by Valgimigli Marco (@vlgmrc) and Colleagues @LaudaniClaudio
https://t.co/iYjPTyvvZn
#Aspirin #CAD #Clopidogrel #CoronaryArteryDisease #ESC2025 #Health #Hematology #HemostasisToday #Lancet #Medicine
hemostasistoday.com
Dirk Sibbing Shares a Recent Study on Clopidogrel Versus Aspirin by Marco Valgimigli and Colleagues
0
1
5
🤔 Do drug-eluting stents increase non-cardiac mortality? A large individual-patient data meta-analysis confirms safety of modern DES compared to older bare-metal stents. Read more ⬇️ https://t.co/mga7onz7W5
#CJC
0
2
10
I am thrilled to announce that we have opened a fully paid PhD position at Cardiocentro Ticino Institute in Switzerland for research in the field of interventional cardiology. Please consult our website for more info if interested
cardiocentro.org
A PhD Position in Clinical and Translational Research in Interventional Cardiology is available at the Interventional Cardiology Unit of Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, and...
2
7
25
Yes, the data was always there - glad this meta-analysis was done to demonstrate it! Start implementing this practice today, especially when DAPT is discontinued post-PCI or ACS.
Practice-changing meta-analysis presented by @vlgmrc at #ESCCongress2025 and published in @TheLancet.
4
15
80
🚀 PANTHER-2 Clopidogrel monotherapy is superior to aspirin monotherapy for MACCE prevention with no increase in the risk of bleeding in patients with established CAD #ESCCongress 💊 Online 👉 https://t.co/BxwmGa49bo
@escardio @vlgmrc @TheLancet
#Pharmacotherapy
2
62
171
Spectacular presentation by @vlgmrc on whether 12 month DAPT duration should be the default strategy after ACS.
2
6
21
The Onsite #EAPCI Coronary Course 🚀 Registration is open 🗓️ 9–10 October 2025 📍 Hotel East Cosmos, Hamburg 🇩🇪 Thrilled to announce these unique learning together with the Course Director, Erik Rafflenbeul (@KardiologieHH ) 🙌 👉 2 days full of interactive #Workshops,
1
13
28
Radial access for PCI: the good, the better, and the ugly @vlgmrc ➡️ https://t.co/dXPcjR62Jb Our editorial on a recent study from the NCDR CathPCI registry @SVRaoMD @rwyeh
academic.oup.com
This editorial refers to ‘Radial vs femoral access for percutaneous coronary intervention: temporal trends and outcomes in the USA’, by R. Fazel et al., ht
0
3
3
He’s the best!
Fantastic talk by @SVRaoMD on #ACS guidelines #AHA #ACC @CircAHA @cvinnovations #CVI2025 @HollandTamis @HenrytTimothy @ChangeAtHeart @chadialraies @FarshadForouz @esbrilakis @arnoldseto @timir_paul @Pooh_Velagapudi @rajivxgulati @RhianEDavies1 @calmanoj @HarisPatail
0
2
5
For all those who want to extend the focus beyond the first few months after ACS/PCI please attend the following clinical trial session @escardio in Madrid
To all enthusiasts of platelets, hemostasis, and thrombosis: ESC Hot Line Session 7, focused on antiplatelet therapy in ACS/PCI, is notable for the coincidental fact that all featured trials had their protocol designs published in EuroIntervention. This is gratifying, as it
1
3
21
Its CoFi time! We are absolutely thrilled to announce the FDA approval of the MOCA II IDE pivotal trial and cannot wait to get sites up and recruiting in this landmark trial for CorFlow. Want to learn more about MVO and STEMI? https://t.co/Gbdfuig9BA
0
3
2
I am pleased to announce that the new Impact Factor of EuroIntervention is the highest in its 20-year history: 9.5. Ranked 16th out of 230 journals in the cardiovascular category (+5 positions versus the previous year). Thank you all — it’s an exciting rollercoaster.
26
49
194
Giving a P2Y12 inhibitor to patients with coronary artery disease is associated with lower rates of myocardial infarction and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds this study @vlgmrc
https://t.co/2j9acxYq35
bmj.com
Objective To assess the long term comparative effectiveness of P2Y12 inhibitor monotherapy compared with aspirin monotherapy in patients after percutaneous coronary intervention (PCI) and discontin...
1
6
17